Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193180 · ClinicalTrials.gov registry record · Phase 2
Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 6
- Study locations
NCT00193180 is a Phase 2 study of Breast Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 37 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT00193180, a Phase 2 study of Breast Cancer, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 6
- Study locations
Study Summary
This trial evaluates the novel combination of docetaxel with imatinib as first or second line therapy in advanced breast cancer with the aim of achieving higher effectiveness and potentially reducing side effects.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Imatinib
Study Locations (6)
Georgia
- Northeast Georgia Medical Center - Gainesville
Kentucky
- Consultants in Blood Disorders and Cancer - Louisville
Louisiana
- Baton Rouge General Medical Center - Baton Rouge
Nebraska
- Methodist Cancer Center - Omaha
Ohio
- Oncology Hematology Care - Cincinnati
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2005-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193180
The ClinicalTrials.gov registry entry for NCT00193180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT00193180 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Kentucky, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00193180 about?
NCT00193180 is a clinical study titled "Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer". This trial evaluates the novel combination of docetaxel with imatinib as first or second line therapy in advanced breast cancer with the aim of achieving higher effectiveness and potentially reducing side effects.
What is the current status of trial NCT00193180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2005-05. Estimated completion is 2009-01.
What conditions does trial NCT00193180 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00193180?
The interventions under investigation include: Docetaxel (DRUG), Imatinib (DRUG).
Who is sponsoring clinical trial NCT00193180?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00193180 being conducted?
This trial has 6 study locations across Georgia, Kentucky, Louisiana, Nebraska, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.